RO7123520 + methotrexate + anti-TNF-alpha

**RO7123520 + methotrexate + anti-TNF-alpha** is an experimental combination therapy studied for the treatment of moderately to severely active rheumatoid arthritis in patients who have had an inadequate response to standard-of-care therapies (including methotrexate and anti-TNF-alpha agents). RO7123520 is a small molecule drug developed by F. Hoffmann-La Roche Ltd., with discontinued development after phase 2 trials. The combination targets multiple arms of the inflammatory cascade: RO7123520’s precise mechanism is not fully specified in the available data, but methotrexate acts as a folate antimetabolite immunosuppressant, and anti-TNF-alpha agents (such as infliximab, adalimumab, etanercept) are biologics that neutralize tumor necrosis factor alpha (TNF-alpha), a key cytokine in autoimmune inflammation. This combination was investigated in a phase 2, randomized, placebo-controlled study as adjunct therapy to standard methotrexate and anti-TNF-alpha treatment[1][3][5].